Pliant Therapeutics Net Income vs. Debt To Equity
| PLRX Stock | USD 13.34 0.13 0.98% |
Net Loss | First Reported 2019-03-31 | Previous Quarter -55.9 M | Current Value -57.8 M | Quarterly Volatility 21.1 M |
| Current Value | Last Year | Change From Last Year | 10 Year Trend | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Gross Profit Margin | 0.48 | 0.56 |
|
|
For Pliant Therapeutics profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Pliant Therapeutics to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Pliant Therapeutics utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Pliant Therapeutics's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Pliant Therapeutics over time as well as its relative position and ranking within its peers.
Pliant |
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Pliant Therapeutics. If investors know Pliant will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Pliant Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (3.35) | Quarterly Revenue Growth (1.00) | Return On Assets (0.28) | Return On Equity (0.48) |
The market value of Pliant Therapeutics is measured differently than its book value, which is the value of Pliant that is recorded on the company's balance sheet. Investors also form their own opinion of Pliant Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Pliant Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Pliant Therapeutics' market value can be influenced by many factors that don't directly affect Pliant Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Pliant Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Pliant Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Pliant Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Pliant Therapeutics Debt To Equity vs. Net Income Fundamental Analysis
Comparative valuation techniques use various fundamental indicators to help in determining Pliant Therapeutics's current stock value. Our valuation model uses many indicators to compare Pliant Therapeutics value to that of its competitors to determine the firm's financial worth. Pliant Therapeutics is regarded fifth in net income category among its peers. It is regarded third in debt to equity category among its peers . Pliant Therapeutics reported Net Loss of (161.34 Million) in 2023. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Pliant Therapeutics' earnings, one of the primary drivers of an investment's value.Pliant Debt To Equity vs. Net Income
Net income is the profit of a company for the reporting period, which is derived after taking revenues and gains and subtracting all expenses and losses. Net income is one of the most-watched numbers by money managers as well as individual investors.
Pliant Therapeutics |
| = | (161.34 M) |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
Debt to Equity is calculated by dividing the Total Debt of a company by its Equity. If the debt exceeds equity of a company, then the creditors have more stakes in a firm than the stockholders. In other words, Debt to Equity ratio provides analysts with insights about composition of both equity and debt, and its influence on the valuation of the company.
Pliant Therapeutics |
| = | 0.11 % |
High Debt to Equity ratio typically indicates that a firm has been borrowing aggressively to finance its growth and as a result may experience a burden of additional interest expense. This may reduce earnings or future growth. On the other hand a small D/E ratio may indicate that a company is not taking enough advantage from financial leverage. Debt to Equity ratio measures how the company is leveraging borrowing against the capital invested by the owners.
Pliant Debt To Equity Comparison
Pliant Therapeutics is currently under evaluation in debt to equity category among its peers.
Pliant Therapeutics Profitability Projections
The most important aspect of a successful company is its ability to generate a profit. For investors in Pliant Therapeutics, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Pliant Therapeutics will eventually generate negative long term returns. The profitability progress is the general direction of Pliant Therapeutics' change in net profit over the period of time. It can combine multiple indicators of Pliant Therapeutics, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
| Last Reported | Projected for Next Year | ||
| Accumulated Other Comprehensive Income | 345 K | 362.2 K | |
| Net Loss | -111 M | -105.4 M | |
| Net Interest Income | 19.2 M | 20.2 M | |
| Interest Income | 20.5 M | 21.5 M | |
| Operating Income | -184.1 M | -174.9 M | |
| Net Loss | -155.3 M | -147.5 M | |
| Income Before Tax | -161.3 M | -153.3 M | |
| Total Other Income Expense Net | 22.8 M | 23.9 M | |
| Net Loss | -161.3 M | -153.3 M | |
| Income Tax Expense | 1.7 M | 1.8 M | |
| Non Operating Income Net Other | 4.5 M | 4.7 M | |
| Change To Netincome | 26 M | 27.3 M | |
| Net Loss | (2.75) | (2.88) | |
| Income Quality | 0.72 | 0.69 | |
| Net Income Per E B T | 0.89 | 0.59 |
Pliant Profitability Driver Comparison
Profitability drivers are factors that can directly affect your investment outlook on Pliant Therapeutics. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Pliant Therapeutics position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Pliant Therapeutics' important profitability drivers and their relationship over time.
Use Pliant Therapeutics in pair-trading
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Pliant Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Pliant Therapeutics will appreciate offsetting losses from the drop in the long position's value.Pliant Therapeutics Pair Trading
Pliant Therapeutics Pair Trading Analysis
The ability to find closely correlated positions to Pliant Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Pliant Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Pliant Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Pliant Therapeutics to buy it.
The correlation of Pliant Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Pliant Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Pliant Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Pliant Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Use Investing Themes to Complement your Pliant Therapeutics position
In addition to having Pliant Therapeutics in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Biotech Thematic Idea Now
Biotech
Companies specialized in biotechnology production and delivery of pharmaceuticals services. The Biotech theme has 44 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Biotech Theme or any other thematic opportunities.
| View All Next | Launch |
Additional Tools for Pliant Stock Analysis
When running Pliant Therapeutics' price analysis, check to measure Pliant Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Pliant Therapeutics is operating at the current time. Most of Pliant Therapeutics' value examination focuses on studying past and present price action to predict the probability of Pliant Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Pliant Therapeutics' price. Additionally, you may evaluate how the addition of Pliant Therapeutics to your portfolios can decrease your overall portfolio volatility.